Key result
A 9-mm VSD occluder successfully seals the apex with minimal blood loss after transapical TAVR.
Case Report (n=1)
A ventricular septal defect occluder can be feasibly used for apical closure after transapical TAVR, representing a step toward fully percutaneous procedures.
Answers are grounded in this paper and cite their sources.
May facilitate apical hemostasis after transapical TAVR; hypothesis-generating and should not yet change practice.
During transapical transcatheter aortic valve replacement (TA-TAVR), the apical closure remains a challenge for the surgeon, having the risk for ventricular tear and massive bleeding. Apical closure devices are already under clinical evaluation, but only a few can lead to a full percutaneous TA-TAVR. We describe the successful use of a 9-mm myocardial occluder (ventricular septal defect occluder) that was used to seal the apex after a standard TA-TAVR (using the Sapien XT 23-mm transcatheter valve and the Ascendra + delivery system). The placement of the nonmodified myocardial occluder was performed through the Ascendra + delivery system, with a very small amount of blood loss and an acceptable sealing of the apical tear. This approach is feasible and represents a further step toward true-percutaneous transapical heart valve procedures. Modified apical occluders are under evaluation in animal models.
No takes yet. Share an insight, caveat, or question.
Ferrari et al. (2015) conducted a case report in Transapical transcatheter aortic valve replacement (TA-TAVR) (n=1). 9-mm myocardial occluder (ventricular septal defect occluder) was evaluated on Apical sealing and blood loss. The use of a 9-mm ventricular septal defect occluder successfully sealed the apex with minimal blood loss after a standard transapical transcatheter aortic valve replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: